Sagimet Biosciences Inc. Series A closed at $9.99 on Nov 4, up 0.40%, 10.6% below its 52-week closing high. Volume of 756.5K shares was 0.63× its 20-day average (below normal).
Split-adjusted performance: +14.0% over one month, +19.2% over six months, +23.9% over one year.
Short interest was 11.5M shares at the Oct 15 settlement, up 3.0% from the prior report (18.7% of float, 8.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| SGMTSagimet Biosciences Inc. Series A | $9.99 | +0.40% | +19.2% | — | — | — | $708.4M | |
| WVEWave Life Sciences | $3.62 | +1.12% | −50.3% | +72.9% | −470.5% | — | $714.0M | Compare |
| GERNGeron | $1.08 | +16.13% | −31.6% | +17.2% | −29.0% | — | $693.9M | Compare |
| OBXObsidian Therapeutics | $10.99 | −16.93% | — | — | — | — | $678.9M | Compare |
| KURAKura Oncology | $7.61 | −22.98% | −20.4% | +36.5% | −327.3% | — | $677.0M | Compare |
| DSGNDesign Therapeutics | $10.63 | +2.80% | −26.9% | — | — | — | $665.2M | Compare |
| AVBPArriVent BioPharma | $13.49 | +3.61% | −54.5% | — | — | — | $665.2M | Compare |
| ZVRAZevra Therapeutics | $11.17 | +8.87% | −0.7% | +44.9% | 48.8% | 8.6 | $663.3M | Compare |
| IMMXImmix Biopharma | $7.97 | +3.37% | −22.8% | — | — | — | $660.7M | Compare |
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
